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Abstract
Purpose To assess factors inﬂuencing the long-term
survival of elderly dialysis patients.
Methods The study group consisted of 51 prevalent
dialysis patients aged over 70 years (32 F and 19 M,
all caucasians), who had been on a chronic hemodi-
alysis (27) or peritoneal dialysis program (24) for at
least2 months;medianagewas77 years,mediantime
on dialysis before inclusion was 16 months, and
median residual diuresis was 600 ml. The patients
were prospectively followed up to 4 years, and an
analysis of factors affecting survival was performed.
Results Thirteen patients from the initial cohort of
51 (25.5 %) survived the whole 48-month observation
period: 10 HD patients (37 %) and 3 PD patients
(12.5 %). Annual mortality rate was 28.2 %: 37.4 %
on PD vs. 20.9 % on HD. The dialysis modality had a
signiﬁcant impact on patients’ survival (p = 0.049;
Cox F-test). The independent mortality risk factors in
the Cox proportional hazard regression model were
higher plasma pro-atrial natriuretic peptide (pro-ANP)
(p = 0.006), lower residual diuresis (p = 0.048), and
lower systolic blood pressure (BP) value (p = 0.039).
Conclusions Paramount for the survival of the
elderly on dialysis is adequate extracellular volume
control. Residual renal function is a protective factor
for the survival of elderly HD patients. This observa-
tion is novel, not previously reported in an elderly
dialysis population.
Keywords Elderly  Hemodialysis  Peritoneal
dialysis  Survival  Extracellular volume control
Introduction
Thepopulationofpatients withchronickidneydisease
isgrowing,despiteprogress inpreventivemeasures, at
a rate of 5–8 % per year [1, 2].
The greatest increase in the incidence and preva-
lence of end-stage renal disease (ESRD) is occurring
among the elderly, who simultaneously constitute the
most fragile subset of dialysis patients, with annual
mortality reaching 25 % [3–6].
This is exempliﬁed by data from the European
registry showingthat48 %ofnewdialysispatientsare
above the age of 65 and have a 2-year survival rate of
51 % [7, 8].
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DOI 10.1007/s11255-012-0166-4A Canadian study found that patients older than 75
hadsurvivalof20.3 %at5 yearsafterdialysisinitiation
[9]. Therefore, an important task of dialysis care is to
reduce the excessive mortality of this frail geriatric
cohort. A substantial step in this direction is the
identiﬁcationofpotentiallyreversiblefactorsnegatively
affecting the long-term survival of dialysis seniors.
This was the aim of our study encompassing a
group of 51 elderly above 70 years, median age
77 years, who had been on maintenance dialysis at
least 2 months, median period 16 months. The
included patients were prospectively followed for
4 years. Additionally, in the study, we compared in
these elderly patients the efﬁcacy of hemodialysis
(HD) and peritoneal dialysis (PD), because both
dialysis modalities were nearly equally distributed.
Materials and methods
The study group was created from 51 prevalent
dialysis patients with aged over 70 years (32 F and
19 M, all Caucasian) who had been on a chronic
hemodialysis (27) or peritoneal dialysis program (24)
for at least 2 months; median age 77 years, median
time on dialysis before inclusion 16 months, and
median residual diuresis 600 ml.
Thepatientswererecruitedfromthreedialysiscenters
in southwest Poland (Wroclaw, Zabrze, Walbrzych).
Twenty-six patients (51 %) were diabetics with the
highly advanced Monckeberg type of arteriosclerosis
with medial intravascular calciﬁcations in the forearm
arteries demonstrated by X-ray.
The group was formed in 2006 and prospectively
observed during the subsequent 4 years.
The patients included in the study were free of
active infection, symptomatic coronary disease, overt
heart failure, history of malignancy, and diseases
requiring immunosuppressive treatment. The protocol
was approved by the local ethics committee. Clinical
data of patients were extracted from the hospital
records.
The impact of the following factors on survival was
tested: baseline characteristics (age, gender, and
race—all caucasian), residual diuresis, duration of
dialysis, all standard indicators of dialysis care (blood
pressure, HGB, BMI, adequacy of dialysis—Kt/V),
and the following laboratory parameters: serum pro-
atrial natriureticpeptide (pro-ANP),serumN-terminal
pro-B-type natriuretic peptide (NT-proBNP), serum
C-reactive protein (CRP), interleukin 6 (IL-6), serum
albumin, and cholesterol.
All HD patients were dialyzed using a native
arteriovenous ﬁstula fulﬁlling a single-pool Kt/V C
1.3. All PD patients were treated by continuous
ambulatory peritoneal dialysis (CAPD) achieving
weekly Kt/V[1.7. Kt/V was calculated from three
consecutive measurements at monthly intervals.
Routine laboratory tests (HGB[g/dl], CRP [mg/l],
serum albumin [g/dl], and cholesterol [mmol/l]) were
measured in the Central Hospital Laboratory as part of
the standard care.
In addition, serum pro-ANP (amino terminal 1–98
ANP fragment) and serum NT-proBNP were assessed
by ELISA (BIOMEDICA, Vienna, Austria); interleu-
kin-6(IL-6)wasmeasuredbyELISA(R&DSystems,
Minneapolis, USA).
The blood samples were taken in HD patients
beforethemidweekdialysis session andinPDpatients
during a control visit at the outpatient clinic during
morning hours before the ﬁrst ﬂuid exchange.
The statistical analysis was performed with Statis-
tica 9.0 software. Univariate methods employed for
the analysis were Pearson’s v
2 test of independence
and Fisher’s exact test (testing associations between
two categorical variables), and nonparametric Mann–
Whitney U test (comparing means of qualitative
variables in two groups). Multivariate analysis was
conducted using the Cox proportional hazard model
(investigating the inﬂuence of qualitative variables on
riskofdeath),andtestsofsurvivaltimeequalityintwo
groups (the Cox F-test and the log-rank test).
Statistical signiﬁcance was recognized with a
p value\0.05. For quantitative variables, results are
given as mean ±SD.
Results
Demographic, clinical, and laboratory parameters of
the investigatedpatients atstudyentry arepresentedin
Table 1.Thedata are shown separately for the HD and
PD patients. There were two signiﬁcant differences
between the groups at the start of the study: signiﬁ-
cantly lower albumin level (p = 0.026) and signiﬁ-
cantly higher cholesterol concentration (p\0.001) in
PD compared to HD patients.
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123Thirteen patients from the initial cohort of 51
(25.5 %) survived the whole 48-month observation
period: 10 HD patients (37 %) and 3 PD patients
(12.5 %). Table 2 contains the clinical characteristics
of the deceased and surviving patients.
In this univariate comparison, the elderly survivors
exhibited signiﬁcantly higher residual diuresis
(p = 0.034) and slightly lower IL-6 (p = 0.054).
The mean annual mortality rate was 28.2 %
(37.4 % on PD vs. 20.9 % on HD).
After the end of the 4-year observation period, the
survival of elderly patients was signiﬁcantly better in
the HD-treated group (p = 0.045 in Pearson’s v
2 test
of independence and p = 0.044 in Fisher’s exact test;
Fig. 1). Type of dialysis modality appeared to be a
factor signiﬁcantly inﬂuencing patients’ survival with
Table 2 Clinical
characteristics of deceased
and surviving patients
* p\0.05, statistically
signiﬁcant;
** 0.05\p\0.1
Characteristics Deceased pts
(n = 38)
Surviving pts
(n = 13)
Mann–Whitney
U test
p value
Age (years) 77.55 ± 3.78 77.23 ± 3.37 0.862
BMI (kg/m2) 25.96 ± 4.40 27.05 ± 3.87 0.418
Duration of dialysis (months) 19.68 ± 16.76 16.62 ± 11.58 0.837
Systolic BP (mmHg) 127.47 ± 14.91 135.69 ± 13.65 0.102
Diastolic BP (mmHg) 78.29 ± 8.94 78.54 ± 8.33 0.893
Residual diuresis (ml/24 h) 540.00 ± 433.08 780.77 ± 313.27 0.034*
Hb (g/dl) 11.29 ± 1.28 11.75 ± 0.85 0.150
CRP (mg/l) 14.30 ± 18.37 7.36 ± 10.32 0.166
IL-6 (pg/ml) 9.72 ± 6.79 6.28 ± 5.34 0.054**
Serum albumin (g/dl) 3.60 ± 0.51 3.88 ± 0.39 0.096**
Cholesterol (mmol/l) 5.38 ± 1.49 4.96 ± 1.38 0.496
Pro-ANP (nmol/l) 1–98 26.52 ± 13.71 20.05 ± 11.16 0.136
NT-proBNP (nmol/l) 1–76 0.31 ± 0.33 0.24 ± 0.17 0.503
Kaplan-Meier Survival Function
Deceased  Surviving
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 HD
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Fig. 1 Kaplan–Meier
survival function. The
difference in mortality
between the elderly patients
during 4-year observation
period according to
modality of dialysis
treatment—PD versus HD
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123PD being inferior to HD (p = 0.049; Cox F-test). The
most common causes of death were as follows:
cardiovascular complications 23 pts (60 %) (12 PD/
11 HD), infection 12 pts (32 %) (7 PD/5 HD),
malignancy 2 pts (10 %) (1 PD/1 HD), and unknown
reasons 1 PD pt (3 %).
The independent variables with a signiﬁcant nega-
tive impact on 4-year survival of the followed elderly
dialysis patients in the Cox proportional hazard
regression model (Table 3) were as follows: higher
plasma pro-ANP (p = 0.006), lower residual diuresis
(p = 0.048), and lower systolic BP value (p = 0.039).
Referring to the dialysis modality, the Cox propor-
tional hazard regression model showed a signiﬁcant
association of mortality with higher plasma pro-ANP
(p = 0.008) and lower systolic BP value (p = 0.043)
inPDpatientsversuslessresidualdiuresis(p = 0.005)
and lower BMI (p = 0.017) in HD patients. It is worth
emphasizing that in this geriatric cohort with age
ranging from 71 up to 86 years, the presence of
diabetes did not exert a negative impact on survival.
Discussion
An important element of the study is its performance
in the cohort of elderly dialysis patients who survived
the ﬁrst adaptive and disruptive phase of dialysis
treatment, having been on maintenance dialysis at
least 2 months, with a median period of dialysis
therapy before inclusion of 16 months. Other note-
worthy distinctive features of the investigated patients
were the absence of overt heart failure and symptom-
atic coronary disease, native arteriovenous ﬁstula as
vascular access in all subjects, and nearly equal
distribution of individuals between HD and PD
treatment. However, two metabolic differences
appeared between patients treated by the different
dialysis modalities. PD patients exhibited signiﬁcantly
lower albumin and signiﬁcantly higher cholesterol
values.Inotheraspects,thegroupswerewellmatched.
About 25.5 % of the study patients survived the
whole 4-year observation period. Ten survivors were
on maintenance dialysis and 3 remained on PD. In
univariate analysis, the elderly survivors displayed
signiﬁcantly higher residual diuresis and slightly
lower IL-6. In multivariate evaluation (Table 3), the
independent variables with a negative prognostic
impact on 4-year survival were found to be higher
plasma pro-ANP, lower residual diuresis, and lower
systolic BP value. This reﬂects the particular impor-
tanceofmeticulousextracellularvolumecontrolinthe
frail elderly population. The consequence of volume
overload is left ventricular hypertrophy, and ﬁnally,
the diminishment of cardiac performance manifested
by lower systolic BP [10].
In our study, pro-ANP determination showed a
prognostic advantage over NT-proBNP measurement.
Elevated pro-ANP level appeared to be an indepen-
dent predictor of mortality, whereas the NT-proBNP
concentration did not exhibit a signiﬁcant effect. This
difference could be caused by diverse mechanisms of
pro-ANP and NT-proBNP synthesis. ANP is secreted
mainly by the right atrium, while BNP is produced by
cardiac ventricles. ANP has been found to be more
sensitive to changes in intravascular volume, but BNP
level is more related to left ventricular mass and
function [11–13]. The prognostic superiority of pro-
ANP measurement over NT-proBNP determination in
our study population—contradictory to what is
observed in cardiac failure patients [14]—is probably
theconsequenceofconsideringovertcardiacfailureas
antheexclusioncriterion.Inthestudygroupcreatedin
this manner, homogeneous in terms of cardiac struc-
ture, the overhydration reﬂected by pro-ANP levels
appeared to be the decisive factor for survival. We are
conscious of our study’s limitation based on the single
measurement, and we would emphasize the need for
more extensive research before the obtained results
could be applied to the general dialysis population.
The mean annual rate of mortality in the study
group was 28.2 %.
These high mortality rates mirror the poor clinical
situation of elderly dialysis patients. In the recently
publisheddialysis outcomesand practicepatternstudy
(DOPPS), encompassing the largest cohort of hemod-
ialysis patients C75 years, the annual mortality rate
Table 3 Cox proportional hazard regression model
Effect Estimate Wald statistics p value
Pro-ANP 0.032873 7.309433 0.006863
Residual diuresis -0.000995 3.893089 0.048494
Systolic BP -0.024529 4.226666 0.039802
Dependent variable: survival time from beginning of
investigation (n = 51)
Int Urol Nephrol (2012) 44:955–961 959
123was 21.4 % [15]. This indicates that our study group,
although limited in size, is representative.
After the end of the 4-year observation period, the
survival of elderly patients was signiﬁcantly better in
the HD-treated group (Fig. 1). This is in contrast to a
recently published Spanish study where no signiﬁcant
differences in survival was found between PD and HD
patients [16]. However, it should be underscored that
PD patients in our study had a signiﬁcantly lower
albumin level and signiﬁcantly higher cholesterol
concentration, which could negatively affect their
survival.
In relation to the dialysis modality, the Cox
proportional hazard regression model exhibited a
signiﬁcant association of mortality with higher plasma
pro-ANP and lower systolic BP value in PD patients
versus less residual diuresis and lower BMI in HD
patients. This separate analysis again proves the
signiﬁcance of appropriate volume control in the
elderly population, illustrating in the PD group the
aforementioned relationship between volume over-
load and impaired cardiac performance.
Of particular note are the data showing that in HD
patients, the drop of residual diuresis was the strongest
mortality risk factor. It is according to our knowledge
the ﬁrst such observation in the literature on HD in
elderly patients. The issue of residual renal function is
widelyrecognizedinPDtreatmentevaluation,whereas
information on the impact of residual renal function on
the survival of HD patients is very scanty. We found
only one paper showing in the whole HD population,
without particular reference to the elderly, that the
presenceofresidualrenalfunctionwasprotectiveasan
independent factor against mortality [17].
Another study brought evidence on the positive
relationship between the presence of residual renal
function and overall nutritional status in chronic
hemodialysis patients [18].
Collectively, these data indicate that residual renal
function, which is frequently ignored in HD patients,
should be scrupulously evaluated in the elderly, being
considered as guidance for dialysis regimen prescrip-
tion. The value of nourishment for the survival of
elderly HD patients was shown in our investigation by
revealing lower BMI as an independent mortality risk
factor.
The most common causes of death were cardio-
vascular complications in 60 % of pts, infection in
32 %, and malignancy in 10 %. This breakdown of
causes ofdeathissimilartothatobserved inthelargest
published cohort of elderly patients in the DOPPS
study [15].
Conclusions
1. Pivotal for the survival of elderly dialysis patients
is obtaining the appropriate extracellular volume
control.
2. Residual renal function plays a protective role for
the survival of elderly HD patients.
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